Lung Cancer Prevalence in Iran by Histologic Subtypes

Vardanjani, Hossein Molavi; Zeinali, Masoud; Radmerikhi, Samera; Hadipour, Maryam

Lung Cancer Prevalence in Iran by Histologic Subtypes

Document Type : Original Article

Authors

¹ Iranshahr University of Medical Sciences, Iranshahr; Department of Epidemiology, Shiraz University of Medical Sciences, Shiraz, Iran

² Social Determinants of Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran

³ Fasa University of Medical Sciences, Fasa, Iran

Abstract

Background: Prevalence statistics are essential for cancer control in addition to incidence and mortality data. As we know, there is no published report regarding lung cancer (LC) prevalence in Iran. Herein, we provide model-based estimates of limited time LC prevalence in Iran, 2015. Materials and Methods: Incidence numbers of LC were extracted from Iranian National Cancer Registry reports for 2003–2009. Trends were analyzed by joinpoint regression, assuming a logarithmic poisson model. Incidence numbers were projected up to 2015, using linear regression models which were trained by corrected annual percentage changes. A Monte Carlo-based model was generated, and absolute survival rates, number of incident cases, and incompleteness of Iranian cancer registry for LC were included into it. Limited-time prevalence (within 1, 2–3, and 4–5 years from diagnosis) and its respective 95% uncertainty level (UL) were estimated by age, gender, and histopathological type. Results: Five-year prevalence was estimated to be 4.21 (95% UL: 3.37–5.38) per 100,000 adult person, with a male:female ratio of 2.01. Estimated number of patients within 1, 2–3, and 4–5 years from diagnosis were 1871 (1497–2392), 993 (770–1285), and 420 (322–550), respectively. Most prevalent form of LC were squamous cell carcinoma (802; 579–999) and adenocarcinoma (319; 230–389) in males and females, respectively. Conclusion: According to our results, the most plausible estimates of number of alive LC patients within initial treatment, clinical follow-up, and cure phases were 2392, 1285, and 550 cases in Iran in 2015.

Keywords

References

1.	Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA Oncol 2015;1:505-27.
2.	Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol 2009;20:556-63.
3.	Vahedi M, Pourhoseingholi MA, Baghestani A, Abadi A, Sobhi S, Fazeli Z. Bayesian analysis of lung cancer mortality in the presence of misclassification. Iran J Cancer Prev 2013;6:1-5.
4.	Somi MH, Farhang S, Mirinezhad SK, Naghashi S, Seif-Farshad M, Golzari M. Cancer in East Azerbaijan, Iran: Results of a population-based cancer registry. Asian Pac J Cancer Prev 2008;9:327-30.
5.	Babaei M, Mousavi S, Malek M, Tosi G, Masoumeh Z, Danaei N, et al. Cancer occurrence in Semnan Province, Iran: Results of a population-based cancer registry. Asian Pac J Cancer Prev 2005;6:159-64.
6.	Zahir ST, Mirtalebi M. Survival of patients with lung cancer, Yazd, Iran. Asian Pac J Cancer Prev 2012;13:4387-91.
7.	Abazari M, Gholamnejad M, Roshanaei G, Abazari R, Roosta Y, Mahjub H. Estimation of survival rates in patients with lung cancer in west Azerbaijan, the northwest of Iran. Asian Pac J Cancer Prev 2015;16:3923-6.
8.	Carpenter WR, Yeh WS, Wobker SE, Godley PA. Getting cancer prevalence right: Using state cancer registry data to estimate cancer survivors. Cancer Causes Control 2011;22:765-73.
9.	Vardanjani HM, Baneshi MR, Haghdoost A. Total and partial prevalence of cancer across Kerman Province, Iran, in 2014, using an adapted generalized network scale-up method. Asian Pac J Cancer Prev 2015;16:5493-8.
10.	Moradpour F, Fatemi Z. Estimation of the projections of the incidence rates, mortality and prevalence due to common cancer site in Isfahan, Iran. Asian Pac J Cancer Prev 2013;14:3581-5.
11.	Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013;132:1133-45.
12.	Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002;97:72-81.
13.	GLOBOCAN 2012, Islamic Republic of Iran, Estimated Incidence and Prevalence, Adult Population: Both Sexes. France: IARC; 2013. Available from: http://www.globocan.iarc.fr/old/summary_table_pop_prev.asp?selection=91364&title=Iran%2C+Islamic+Republic+of&sex=0&window=1&sort=0&submit=%C2%A0Execute.[Last cited on 2016 Feb 14].
14.	Zendehdel K, Sedighi Z, Hassanloo J, Nahvijou A. Audit of a nationwide pathology-based cancer registry in Iran. Basic Clin Cancer Res 2011;3:7-13.
15.	Marzban M, Haghdoost AA, Dortaj E, Bahrampour A, Zendehdel K. Completeness and underestimation of cancer mortality rate in Iran: A report from Fars Province in Southern Iran. Arch Iran Med 2015;18:160-6.
16.	Molavi Vardanjani H. Compeleness of case acertainment at Kerman cancer registry. Kerman: Kerman University of Medical Sciences; 2015.
17.	Gelband H, Sankaranarayanan R, Gauvreau CL, Horton S, Anderson BO, Bray F, et al. Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: Key messages from Disease Control Priorities, 3^rd edition. Lancet 2016;387:2133-44.
18.	Estimated incidence and prevalence, adult populationIslamic Republic of Iran. France: IARC; 2013. Available from: http://www.globocan.iarc.fr/old/summary_table_pop_prev.asp?selection=91364&title=Iran%2C+Islamic+Republic+of&sex=0&window=1&sort=0&submit=%C2%A0Execute. [Last cited on 2016 Feb 14].
19.	Gallus S, Lugo A, La Vecchia C, Boffetta P, Chaloupka FJ, Colombo P, et al. Pricing policies and control of tobacco in Europe (PPACTE) project: Cross-national comparison of smoking prevalence in 18 European countries. Eur J Cancer Prev 2014;23:177-85.
20.	Meysamie A, Ghaletaki R, Haghazali M, Asgari F, Rashidi A, Khalilzadeh O, et al. Pattern of tobacco use among the Iranian adult population: Results of the national survey of risk factors of non-communicable diseases (SuRFNCD-2007). Tob Control 2010;19:125-8.
21.	Jemal A. Lung cancer mortality. CA Cancer J Clin 2003;53:5-26.
22.	Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends by histologic type: Male: female differences diminishing and adenocarcinoma rates rising. Int J Cancer 2005;117:294-9.
23.	de Groot P, Munden RF. Lung cancer epidemiology, risk factors, and prevention. Radiol Clin North Am 2012;50:863-76.
24.	Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E, Bray F. International trends in lung cancer incidence by histological subtype: Adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer 2014;84:13-22.

Advanced Biomedical Research